For the first time, a large clinical trial showed across-the-board cardiovascular benefit of a diabetes drug – liraglutide – a much-needed outcome for people with type 2 diabetes.
Buse led a global clinical trial on the new type-2 diabetes drug iDegLira, and he spoke to the local news station about the best ways to screen for the disease.
The new “smart cell patch” developed at UNC and NC State is a proof of principle to treat millions of people with type-1 and advanced type-2 diabetes.
UNC-led global phase-3 clinical trial sets the stage for improved management of a disease that affects nearly 30 million Americans.
The joint UNC/NC State researcher also earned a grant from JDRF and Sanofi to further develop glucose responsive insulin therapies for diabetes.
Praveen Sethupathy, PhD, earns early-career ADA award to research innovative ways to treat people with diabetes.
The editors of the MIT Technology Review highlighted Gu’s work on a novel way to monitor and treat diabetes.
New study in Diabetes Care suggests new delayed-release metformin could help 40 percent of type 2 diabetes patients that currently can’t take metformin.
The finding published in PLoS One suggests that elevated oxidized LDL cholesterol and fructosamine – a measure of glycated proteins in blood sugar – are signposts for the development of severe coronary disease, especially in females.
A joint effort between diabetes doctors and biomedical engineers could revolutionize how people with diabetes keep their blood sugar levels in check.
TV segment focused diabetes prevention and screening and featured John Buse, MD, PhD, chief, Division of Endocrinology, executive associate dean for clinical research.
The research by Zhen Gu, PhD, assistant professor in the UNC-NCSU joint department of biomedical engineering, aims to improve methods for delivering precise amounts of medications less frequently.
By treating people earlier, doctors could help diabetes patients avoid the most severe, life-threatening complications that stem from prolonged periods of elevated blood glucose.
UNC researchers overturn a controversial study about DPP-4 inhibitors – commonly prescribed diabetes medications.
Participating in the chat will be two diabetes experts and co-authors of a new American Diabetes Association position statement on the care of people with type 1 diabetes.
The Bamberg Diabetes Transitional Care Study will utilize cutting-edge iPad technology to explore the impact and feasibility of different diabetes interventions for patients transitioning from the hospital to home.
John B. Buse, MD, PhD, chief of the division of endocrinology and director of the Diabetes Care Center, has been ranked as one of the world’s foremost experts in type 2 diabetes based on an analysis of publications in the National Library of Medicine’s MEDLINE database.
The newest American Diabetes Association treatment guidelines for the disease are in place at UNC Medical Center.
Collaboration will leverage big data to help providers engage patients to manage diabetes, improve health
The ENDO Trial is currently enrolling adults between the ages of 21 and 65 who have uncontrolled type 2 diabetes and are obese.